Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy

키워드

참고문헌 (39)

1. Wei SC, "Fundamental mechanisms of immune checkpoint blockade therapy", Cancer Discov, 8, pp.1069~1086 (2018)
2. Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
3. Jenkins RW, "Mechanisms of resistance to immune checkpoint inhibitors", Br J Cancer, 118, pp.9~16 (2018)
4. Chen PL, "Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade", Cancer Discov, 6, pp.827~837 (2016)
5. Li J, "Tumor cellintrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy", Immunity, 49, pp.178.e7~193.e7 (2018)
6. Binnewies M, "Understanding the tumor immune microenvironment(TIME)for effective therapy", Nat Med, 24, pp.541~550 (2018)
7. Chen DS, "Elements of cancer immunity and the cancer-immune set point", Nature, 541, pp.321~330 (2017)
8. Zlotnik A, "The chemokine superfamily revisited", Immunity, 36, pp.705~716 (2012)
9. Griffith JW, "Chemokines and chemokine receptors : positioning cells for host defense and immunity", Annu Rev Immunol, 32, pp.659~702 (2014)
10. Nagarsheth N, "Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy", Nat Rev Immunol, 17, pp.559~572 (2017)
11. Nibbs RJ, "Immune regulation by atypical chemokine receptors", Nat Rev Immunol, 13, pp.815~829 (2013)
12. Balkwill F, "Cancer and the chemokine network", Nat Rev Cancer, 4, pp.540~550 (2004)
13. Zou W, "Immunosuppressive networks in the tumour environment and their therapeutic relevance", Nat Rev Cancer, 5, pp.263~274 (2005)
14. Groom JR, "CXCR3 ligands : redundant, collaborative and antagonistic functions", Immunol Cell Biol, 89, pp.207~215 (2011)
15. Zhang L, "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer", N Engl J Med, 348, pp.203~213 (2003)
16. Pagès F, "Effector memory T cells, early metastasis, and survival in colorectal cancer", N Engl J Med, 353, pp.2654~2666 (2005)
17. Peng D, "Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy", Nature, 527, pp.249~253 (2015)
18. Wang L, "Decitabine enhances lymphocyte migration and function and synergizes with ctla-4 blockade in a murine ovarian cancer model", Cancer Immunol Res, 3, pp.1030~1041 (2015)
19. Kryczek I, "CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers", Cancer Res, 65, pp.465~472 (2005)
20. Scotton CJ, "Epithelial cancer cell migration: a role for chemokine receptors?", Cancer Res, 61, pp.4961~4965 (2001)
21. Bertolini F, "CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma", Cancer Res, 62, pp.3106~3112 (2002)
22. Rubin JB, "A smallmolecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors", Proc Natl Acad Sci U S A, 100, pp.13513~13518 (2003)
23. O'Hara MH, "Safety and pharmacokinetics of cxcr4 peptide antagonist, ly2510924, in combination with durvalumab in advanced refractory solid tumors", J Pancreat Cancer, 6, pp.21~31 (2020)
24. Castellino F, "Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction", Nature, 440, pp.890~895 (2006)
25. Oelkrug C, "Enhancement of T cell recruitment and infiltration into tumours", Clin Exp Immunol, 178, pp.1~8 (2014)
26. Trifilo MJ, "The CC chemokine ligand 3 regulates CD11c+CD11b+CD8α-dendritic cell maturation and activation following viral infection of the central nervous system : implications for a role in T cell activation", Virology, 327, pp.8~15 (2004)
27. Song R, "Effects of MIP-1 α, MIP-3 α, and MIP-3 β on the induction of HIV Gag-specific immune response with DNA vaccines", Mol Ther, 15, pp.1007~1015 (2007)
28. Griss J, "B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma", Nat Commun, 10, pp.4186~ (2019)
29. Sektioglu IM, "Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells", Cancer Res, 77, pp.291~302 (2017)
30. Juneja VR, "PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity", J Exp Med, 214, pp.895~904 (2017)
31. Allen F, "CCL3 augments tumor rejection and enhances CD8+T cell infiltration through NK and CD103+dendritic cell recruitment via IFNγ", OncoImmunology, 7, pp.e1393598~ (2017)
32. Qian BZ, "CCL2recruits inflammatory monocytes to facilitate breast-tumour metastasis", Nature, 475, pp.222~225 (2011)
33. Pollard JW, "Tumour-educated macrophages promote tumour progression and metastasis", Nat Rev Cancer, 4, pp.71~78 (2004)
34. Kitamura T, "CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages", J Exp Med, 212, pp.1043~1059 (2015)
35. Azenshtein E, "The CC chemokine RANTES in breast carcinoma progression : regulation of expression and potential mechanisms of promalignant activity", Cancer Res, 62, pp.1093~1102 (2002)
36. Stamenkovic I, "Matrix metalloproteinases in tumor invasion and metastasis", Semin Cancer Biol, 10, pp.415~433 (2000)
37. He S, "CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo", J Exp Clin Cancer Res, 29, pp.37~ (2010)
38. Salmon H, "Expansion and activation of CD103(+)dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-l1 and BRAF inhibition", Immunity, 44, pp.924~938 (2016)
39. Ohm JE, "Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo", J Immunol, 163, pp.3260~3268 (1999)

관련 논문AI추천